EU | pharmaphorum

EU

News

scientifically visualization of a coronavirus spike protein

EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine

The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May.

News

Another hurdle down as EU clears AstraZeneca's Alexion takeo...

The European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the UK as the last remaining obstacle to getting the deal across th

News

Keytruda beats Opdivo to first-line oesophageal cancer OK in...

Merck & Co's Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer therapy in the EU, ahead of Bristol-Myers Squibb's rival Opdivo, but BM

News

Libtayo gets a double with EU approvals in skin, lung cancer

Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-

News

AZ, MSD's Koselugo is first EU therapy for neurofibromatosis

The European Commission has approved AstraZeneca and MSD's Koselugo for a rare genetic condition that causes tumours to develop on the covering of nerve cells, leading to disfigurement and

News

After FDA rejection, EU says yes to Sanofi's Aubagio in kids...

Sanofi's Aubagio has become the first oral therapy approved for first-line use in children and adolescents with multiple sclerosis in the EU, a few days after the same indication was turned

EMA starts review of latecomer GSK/Sanofi COVID-19 vaccine

Another hurdle down as EU clears AstraZeneca's Alexion takeo...

Keytruda beats Opdivo to first-line oesophageal cancer OK in...

Libtayo gets a double with EU approvals in skin, lung cancer

AZ, MSD's Koselugo is first EU therapy for neurofibromatosis

After FDA rejection, EU says yes to Sanofi's Aubagio in kids...

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

EU

Editor's Picks